<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486328</url>
  </required_header>
  <id_info>
    <org_study_id>UfukU</org_study_id>
    <nct_id>NCT02486328</nct_id>
  </id_info>
  <brief_title>The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy</brief_title>
  <official_title>The Effect of Different Sedation Regimes Administered by Anesthesiologists or Endoscopists on Cognitive Functions in Lower Gastrointestinal System Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ufuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ufuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are different sedation regimes for lower gastrointestinal system endoscopy which can be&#xD;
      administered by anesthesiologists and non-anesthesiologists. This study aims to compare the&#xD;
      effects of propofol/remifentanil combination and midazolam/meperidine combination on early&#xD;
      cognitive function following lower gastrointestinal system endoscopies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedation for lower gastrointestinal system endoscopies can be administered by&#xD;
      anesthesiologists or endoscopists and cognitive dysfunction after this procedure has not been&#xD;
      fully investigated. The aim of this study was to investigate the effect of different sedation&#xD;
      regimes applied by anesthesiologists or endoscopists on early cognitive dysfunction.&#xD;
      Following ethics committee approval and written informed consent, 100 patients were randomly&#xD;
      divided into two groups. In Group MM where drug regime was solely determined by endoscopists,&#xD;
      2 mg midazolam and 20mg meperidine was given intravenously and additional 1-2mg midazolam and&#xD;
      20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) was given when&#xD;
      facial pain scale (FPS) was greater than 3. In Group RP where drug regime was solely&#xD;
      determined by anesthesiologists, 100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil&#xD;
      bolus was administered and additional 0,5 mcg/kg remifentanil bolus was given when FPS was&#xD;
      greater than 3. Bispectral index (BIS) and hemodynamic monitorization was carried out&#xD;
      throughout the procedure and BIS 60-80 with FPS&lt;3 was targeted. The time to Observer&#xD;
      Assessment of Alertness/Sedation Scale (OAAS) score to reach 3 was measured after the&#xD;
      procedure and Trieger Dot Test (TDT) and Digit Symbol Substitution Test (DSST) was repeated&#xD;
      at 5th, 15th and 30th minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Function</measure>
    <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
    <description>As measured by Trieger Dot Test. The test does not have an upper limit; the time taken to complete the test is added to the number of dots missed by the patient and a result is obtained. The lowest score possible is 0. Higher values represent worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cognitive Function</measure>
    <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
    <description>As measured by Digit Symbol Substitution Test. Scale range 0-9. No cut-off value. Higher results represent better outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Analogue Scale Scores From the Baseline</measure>
    <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
    <description>Pain as measured by Visual Analogue Scale. Range 1-10. No cut-off value, Higher results represent worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
    <description>Heart rate as measured in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Pressure</measure>
    <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
    <description>mean arterial blood pressure as measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Oxygen Saturation</measure>
    <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
    <description>peripheral oxygen saturation as measured by pulse oximeter. Units are percentages, Scale range 0-100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Gastrointestinal Dysfunction</condition>
  <condition>Alteration of Cognitive Function</condition>
  <arm_group>
    <arm_group_label>Group MM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group RP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Dosage adjustment</description>
    <arm_group_label>Group MM</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <description>Dosage adjustment</description>
    <arm_group_label>Group MM</arm_group_label>
    <other_name>Demerol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Dosage adjustment</description>
    <arm_group_label>Group RP</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Dosage adjustment</description>
    <arm_group_label>Group RP</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18-65 years of age (ASA I-III risk groups), scheduled for elective&#xD;
             colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Mini mental test (MMT) score&lt;26&#xD;
&#xD;
          -  Amsterdam Preoperative Anxiety and Information Scale (APAIS ) score &gt;10&#xD;
&#xD;
          -  Advanced cardiopulmonary or psychiatric disease&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Known allergy to study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perihan Ekmek√ßi, Assoc Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFUK UNIVERSITY FACULTY OF MEDICINE</affiliation>
  </overall_official>
  <results_reference>
    <citation>Cohen LB, Dubovsky AN, Aisenberg J, Miller KM. Propofol for endoscopic sedation: A protocol for safe and effective administration by the gastroenterologist. Gastrointest Endosc. 2003 Nov;58(5):725-32.</citation>
    <PMID>14595310</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreira AO, Cravo M. Sedation in gastrointestinal endoscopy: Where are we at in 2014? World J Gastrointest Endosc. 2015 Feb 16;7(2):102-9. doi: 10.4253/wjge.v7.i2.102. Review.</citation>
    <PMID>25685266</PMID>
  </results_reference>
  <results_reference>
    <citation>Padmanabhan U, Leslie K, Eer AS, Maruff P, Silbert BS. Early cognitive impairment after sedation for colonoscopy: the effect of adding midazolam and/or fentanyl to propofol. Anesth Analg. 2009 Nov;109(5):1448-55. doi: 10.1213/ane.0b013e3181a6ad31. Epub 2009 Jul 17.</citation>
    <PMID>19617584</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ufuk University</investigator_affiliation>
    <investigator_full_name>Perihan Ekmek√ßi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cognitive dysfunction</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group MM</title>
          <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when facial pain scale (FPS) greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
        </group>
        <group group_id="P2">
          <title>Group RP</title>
          <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group MM</title>
          <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
        </group>
        <group group_id="B2">
          <title>Group RP</title>
          <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="13.6"/>
                    <measurement group_id="B2" value="53.7" spread="10.4"/>
                    <measurement group_id="B3" value="55.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="11.7"/>
                    <measurement group_id="B2" value="73.1" spread="15.5"/>
                    <measurement group_id="B3" value="72.4" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Test</title>
          <description>A test consisting of 11 questions, range is 0 (worst)-30 (best). A score of 23 and lower is considered as cognitive impairment</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="1.3"/>
                    <measurement group_id="B2" value="28.6" spread="1.6"/>
                    <measurement group_id="B3" value="28.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cognitive Function</title>
        <description>As measured by Trieger Dot Test. The test does not have an upper limit; the time taken to complete the test is added to the number of dots missed by the patient and a result is obtained. The lowest score possible is 0. Higher values represent worse outcomes.</description>
        <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Function</title>
          <description>As measured by Trieger Dot Test. The test does not have an upper limit; the time taken to complete the test is added to the number of dots missed by the patient and a result is obtained. The lowest score possible is 0. Higher values represent worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="10.6"/>
                    <measurement group_id="O2" value="40.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="9.2"/>
                    <measurement group_id="O2" value="37.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="7.9"/>
                    <measurement group_id="O2" value="35.4" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cognitive Function</title>
        <description>As measured by Digit Symbol Substitution Test. Scale range 0-9. No cut-off value. Higher results represent better outcomes</description>
        <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Function</title>
          <description>As measured by Digit Symbol Substitution Test. Scale range 0-9. No cut-off value. Higher results represent better outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.2"/>
                    <measurement group_id="O2" value="2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.4"/>
                    <measurement group_id="O2" value="2.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30th minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.4"/>
                    <measurement group_id="O2" value="3.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Analogue Scale Scores From the Baseline</title>
        <description>Pain as measured by Visual Analogue Scale. Range 1-10. No cut-off value, Higher results represent worse outcomes</description>
        <time_frame>Baseline and 5, 15, 30 minutes after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analogue Scale Scores From the Baseline</title>
          <description>Pain as measured by Visual Analogue Scale. Range 1-10. No cut-off value, Higher results represent worse outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes after the procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.1"/>
                    <measurement group_id="O2" value="0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes after the procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.2"/>
                    <measurement group_id="O2" value="0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after the procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Heart rate as measured in beats per minute</description>
        <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart rate as measured in beats per minute</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="15.5"/>
                    <measurement group_id="O2" value="82.6" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="17.8"/>
                    <measurement group_id="O2" value="81.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="16.4"/>
                    <measurement group_id="O2" value="76" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" spread="14.8"/>
                    <measurement group_id="O2" value="69.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" spread="14.8"/>
                    <measurement group_id="O2" value="70.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="16.1"/>
                    <measurement group_id="O2" value="70" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" spread="15"/>
                    <measurement group_id="O2" value="71.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="14.1"/>
                    <measurement group_id="O2" value="73.1" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Pressure</title>
        <description>mean arterial blood pressure as measured in mmHg</description>
        <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Pressure</title>
          <description>mean arterial blood pressure as measured in mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.7" spread="19.5"/>
                    <measurement group_id="O2" value="113.1" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="16.7"/>
                    <measurement group_id="O2" value="104" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.5" spread="16.2"/>
                    <measurement group_id="O2" value="92.9" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.8" spread="17.7"/>
                    <measurement group_id="O2" value="89.3" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" spread="20.4"/>
                    <measurement group_id="O2" value="87.1" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="16.6"/>
                    <measurement group_id="O2" value="100" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" spread="17.2"/>
                    <measurement group_id="O2" value="91.6" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" spread="18.7"/>
                    <measurement group_id="O2" value="94.3" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Oxygen Saturation</title>
        <description>peripheral oxygen saturation as measured by pulse oximeter. Units are percentages, Scale range 0-100.</description>
        <time_frame>Baseline and 1,2,3,5,10,15 and 20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group MM</title>
            <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
          </group>
          <group group_id="O2">
            <title>Group RP</title>
            <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Oxygen Saturation</title>
          <description>peripheral oxygen saturation as measured by pulse oximeter. Units are percentages, Scale range 0-100.</description>
          <units>Percent of oxygenated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="1.9"/>
                    <measurement group_id="O2" value="98.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="2"/>
                    <measurement group_id="O2" value="98" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="1.7"/>
                    <measurement group_id="O2" value="98.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="1.3"/>
                    <measurement group_id="O2" value="98.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="1.6"/>
                    <measurement group_id="O2" value="97.1" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="2.4"/>
                    <measurement group_id="O2" value="98.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="1.6"/>
                    <measurement group_id="O2" value="98.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minute in procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="1.8"/>
                    <measurement group_id="O2" value="98.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group MM</title>
          <description>2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3&#xD;
Midazolam: Dosage adjustment&#xD;
Meperidine: Dosage adjustment</description>
        </group>
        <group group_id="E2">
          <title>Group RP</title>
          <description>100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3&#xD;
Remifentanil: Dosage adjustment&#xD;
Propofol: Dosage adjustment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Perihan Ekmek√ßi</name_or_title>
      <organization>Ufuk University Faculty of Medicine</organization>
      <phone>+903122044000</phone>
      <email>erdogduperi@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

